PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 253 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $230,314,668 | -23.2% | 7,506,997 | +0.3% | 0.01% | -12.5% |
Q2 2023 | $299,782,465 | -2.2% | 7,481,469 | -0.4% | 0.01% | -11.1% |
Q1 2023 | $306,622,996 | +9.5% | 7,513,428 | +3.6% | 0.01% | 0.0% |
Q4 2022 | $279,978,292 | -26.4% | 7,251,445 | +1.4% | 0.01% | -30.8% |
Q3 2022 | $380,553,000 | -8.2% | 7,154,578 | +0.6% | 0.01% | 0.0% |
Q2 2022 | $414,576,000 | -22.1% | 7,111,061 | +2.0% | 0.01% | -7.1% |
Q1 2022 | $531,992,000 | +29.6% | 6,970,555 | +2.2% | 0.01% | +40.0% |
Q4 2021 | $410,451,000 | +9.5% | 6,821,518 | +1.9% | 0.01% | 0.0% |
Q3 2021 | $374,971,000 | -7.2% | 6,695,892 | +0.6% | 0.01% | -9.1% |
Q2 2021 | $404,073,000 | -19.6% | 6,659,080 | -7.2% | 0.01% | -26.7% |
Q1 2021 | $502,787,000 | +18.3% | 7,173,487 | +1.0% | 0.02% | +7.1% |
Q4 2020 | $424,854,000 | +6.1% | 7,099,847 | +6.6% | 0.01% | -6.7% |
Q3 2020 | $400,485,000 | +8.7% | 6,661,399 | -5.1% | 0.02% | 0.0% |
Q2 2020 | $368,443,000 | +61.0% | 7,021,974 | +2.9% | 0.02% | +36.4% |
Q1 2020 | $228,780,000 | -27.9% | 6,823,110 | -2.6% | 0.01% | -8.3% |
Q4 2019 | $317,302,000 | +23.3% | 7,004,499 | +3.6% | 0.01% | +9.1% |
Q3 2019 | $257,313,000 | +78.2% | 6,758,949 | +103.6% | 0.01% | +83.3% |
Q2 2019 | $144,386,000 | +14.4% | 3,319,976 | +0.1% | 0.01% | 0.0% |
Q1 2019 | $126,231,000 | -11.9% | 3,316,602 | -0.4% | 0.01% | -14.3% |
Q4 2018 | $143,323,000 | -11.3% | 3,331,529 | +1.4% | 0.01% | 0.0% |
Q3 2018 | $161,531,000 | +52.3% | 3,286,457 | -0.7% | 0.01% | +40.0% |
Q2 2018 | $106,055,000 | +5.5% | 3,309,060 | +2.5% | 0.01% | 0.0% |
Q1 2018 | $100,550,000 | -33.1% | 3,227,911 | -2.0% | 0.01% | -28.6% |
Q4 2017 | $150,298,000 | +20.5% | 3,292,397 | -0.9% | 0.01% | +16.7% |
Q3 2017 | $124,700,000 | -24.8% | 3,320,893 | -4.5% | 0.01% | -33.3% |
Q2 2017 | $165,914,000 | +14.3% | 3,478,281 | +9.2% | 0.01% | +12.5% |
Q1 2017 | $145,180,000 | +40795.8% | 3,183,787 | +28922.7% | 0.01% | +700.0% |
Q4 2016 | $355,000 | -62.0% | 10,970 | -59.9% | 0.00% | 0.0% |
Q3 2016 | $935,000 | +592.6% | 27,323 | +581.9% | 0.00% | – |
Q2 2016 | $135,000 | +1.5% | 4,007 | +60.5% | 0.00% | – |
Q1 2016 | $133,000 | +54.7% | 2,497 | +122.7% | 0.00% | – |
Q4 2015 | $86,000 | +152.9% | 1,121 | +34.4% | 0.00% | – |
Q3 2015 | $34,000 | -49.3% | 834 | -12.9% | 0.00% | – |
Q2 2015 | $67,000 | -25.6% | 958 | -6.0% | 0.00% | – |
Q1 2015 | $90,000 | 0.0% | 1,019 | 0.0% | 0.00% | – |
Q4 2014 | $90,000 | -93.1% | 1,019 | -92.4% | 0.00% | -100.0% |
Q3 2014 | $1,301,000 | +1284.0% | 13,419 | +1216.9% | 0.00% | – |
Q2 2014 | $94,000 | +51.6% | 1,019 | +13.9% | 0.00% | – |
Q1 2014 | $62,000 | +19.2% | 895 | 0.0% | 0.00% | – |
Q4 2013 | $52,000 | +20.9% | 895 | 0.0% | 0.00% | – |
Q3 2013 | $43,000 | +26.5% | 895 | -24.4% | 0.00% | – |
Q2 2013 | $34,000 | – | 1,184 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |